6 Results for "

H2122

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "H2122" in MCE Product Catalog:

Cat. No.: HY-137497
CAS No.: 300809-71-6
Purity:  99.85%
Target:  

Ras Apoptosis

Research Areas:  

Cancer

KRAS inhibitor-9, a potent KRAS inhibitor (Kd=92 μM), blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 binds to KRAS G12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity. KRAS inhibitor-9 causes G2/M cell cycle arrest and induces apoptosis. KRAS inhibitor-9 selectively inhibits the proliferation of NSCLC cells with KRAS mutation but not normal lung cells .
loading...
    loading...
Cat. No.: HY-124084
CAS No.: 1673556-40-5
Research Areas:  

Cancer

SW203668 is an irreversible stearoyl CoA desaturase (SCD) inhibitor with an IC50 of 54 nM. SW203668 covalently binds and inhibits SCD, depletes unsaturated fatty acids, and triggers cell death in sensitive cells. SW203668 requires demethylation by CYP4F11 to form its active SCD-inhibiting form; differential CYP4F11 expression drives selective cytotoxicity. SW203668 exerts cytotoxicity toward CYP4F11-expressing non-small cell lung cancer (NSCLC) cells and spares CYP4F11-lacking NSCLC cells. SW203668 inhibits tumor growth in immunodeficient mice bearing CYP4F11-expressing NSCLC xenografts and spares mouse skin sebocytes. SW203668 can be used for the research of non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-155209
CAS No.: 1673558-59-2
Research Areas:  

Cancer

SCD1 inhibitor-5 (compound 51) is a SCD1 inhibitor,with the IC50 values​ of 0.13 μM and 31 μM for H2122 and H1819, respectively. SCD1 inhibitor-5 can be used in cancer research .
loading...
    loading...
Cat. No.: HY-124084A
CAS No.: 2117405-48-6
Research Areas:  

Cancer

SW203668 TFA is an irreversible stearoyl CoA desaturase (SCD) inhibitor with an IC50 of 54 nM. SW203668 TFA covalently binds and inhibits SCD, depletes unsaturated fatty acids, and triggers cell death in sensitive cells. SW203668 TFA requires demethylation by CYP4F11 to form its active SCD-inhibiting form; differential CYP4F11 expression drives selective cytotoxicity. SW203668 TFA exerts cytotoxicity toward CYP4F11-expressing non-small cell lung cancer (NSCLC) cells and spares CYP4F11-lacking NSCLC cells. SW203668 TFA inhibits tumor growth in immunodeficient mice bearing CYP4F11-expressing NSCLC xenografts and spares mouse skin sebocytes. SW203668 TFA can be used for the research of non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-121352
CAS No.: 934464-79-6
Target:  

Drug Derivative

Research Areas:  

Cancer

Kibdelone C is a hexacyclic tetrahydroxanthone natural product and anticancer agent with sub-nanomolar GI50 activity against human SR leukemia and SN12C renal carcinoma cell lines. Kibdelone C disrupts the actin cytoskeleton in human cancer cells, leading to cell contraction and actin stress fiber formation, without direct actin binding, actin polymerization effects, topoisomerase I/II inhibition, or DNA binding. Kibdelone C can be used for the research of leukemia, and renal cell carcinoma .
loading...
    loading...
Cat. No.: HY-114606
CAS No.: 1673557-43-1
Research Areas:  

Cancer

SW208108 is a prodrug of dMe-SW208108, a CYP4F11-activated SCD inhibitor, with an IC50 value of 9 nM. SW208108 undergoes demethylation by CYP4F11 to form the active metabolite dMe-SW208108, thereby inhibiting enzyme function. SW208108 depletes unsaturated fatty acids, induces cytotoxicity in non-small cell lung cancer (NSCLC) cells expressing CYP4F11, and does not affect SCD activity in mouse sebocytes. SW208108 can be used in studies related to NSCLC .
loading...
    loading...